噻托溴铵联合沙美特罗替卡松治疗稳定期C组D组慢性阻塞性肺疾病的临床疗效  

Effect of tiotropium bromide and salmeterol fluticasone propionate in treating stable chronic obstructive pulmonary disease at phases of group C and D

作　　者：王集红[1] 刘歆[1] 郭永明[1] 刘宇[1] 刘钦华[1] 陈世谋[1] 吴明[1] 

机构地区：[1]福建医科大学福建省老年医院教学医院,福建省福州市350003

出　　处：《临床合理用药杂志》2015年第21期15-16,共2页Chinese Journal of Clinical Rational Drug Use

摘　　要：目的探讨噻托溴铵联合沙美特罗替卡松治疗稳定期C组D组慢性阻塞性肺疾病(COPD)的临床疗效。方法选取2013年1月一2014年1月福建医科大学福建省老年医院教学医院收治的稳定期C组D组COPD患者78例,随机分为试验组与对照组,各39例。试验组患者予以噻托溴铵联合沙美特罗替卡松治疗,对照组患者予以沙美特罗替卡松治疗。观察两组患者治疗前后临床疗效指标及不良反应发生情况。结果治疗前两组患者血氧分压(Pa O2)、二氧化碳分压(Pa CO2)、慢性阻塞性肺病评估测试(CAT)评分、第1秒用力呼气容积占预计值百分比(FEV1%pred)、第1秒用力呼气容积占肺活量百分比(FEV1/FVC%)、6min步行距离(6MWD)、圣·乔治医院呼吸问题调查问卷(SGRQ)评分比较,差异无统计学意义(P>0.05);治疗后试验组患者Pa O2高于对照组,Pa CO2、CAT评分、SGRQ评分低于对照组,6MWD大于对照组,差异有统计学意义(P<0.05),两组患者FEV1/FVC%、FEV1%pred比较,差异无统计学意义(P>0.05);两组患者均未发生严重不良反应。结论噻托溴铵联合沙美特罗替卡松治疗稳定期C组D组COPD的临床疗效显著,可改善患者临床症状,降低急性发作频率,提高生活质量及运动耐力,且不良反应小。Objective To explore the effect of tiotropium bromide and salmeterol fluticasone propionate in treating stable chronic obstructive pulmonary disease （COPD） at phases of group C and D. Methods A total of 78 patients with stable COPD at phases of greup C and D were selected in Fujian Province Geriatrics Hospital （ the Training Hospital of Fujian Medical University） from January 2013 to January 2014, they were randomly divided into experiment group and control group, 39 cases in each group. Experiment group was given tiotropium bromide and salmeterol fluticasone propionate treatment, control group was given salmeterol fluticasone propionate treatment. Before and after treatment, clinical efficacy index and incidence of adverse reactions between the two groups were compared. Results Before treatment, blood oxygen pressure （PaO2） , PaCO2, chronic obstructive pulmonary disease evaluation test （CAT） score, FEVI% pred, FEV1/FVC%, 6- minute walking distance （6MWD）, St George＇ Hospital Respiratory Problems Questionnaire （SGRQ） score showed no significant differences between the two groups （P 〉 0.05 ） ; after treatment, PaO2 of experiment group was higher than that of control group, PaCO2, CAT score, SGRQ score of experiment group were lower than those of control group, 6MWD of experiment group was more than that of control group （P 〈 O. 05）, FEV1/FVC% , FEV1% pred showed no significant differences between the two groups （P 〉 0.05） ; no one of the two groups occurred serious adverse reactions. Conclusion Tiotropium bromide and salmeterol fluticasone propionate have notable curative effect in the treatment of stable COPD at phases of group C and D, can improve the clinical symptoms, decrease the frequency of acute attack, improve the quality of life and exercise endurance and has less adverse reactions.

关 键 词：肺疾病 慢性阻塞性 噻托溴铵 沙美特罗替卡松 治疗结果 

分 类 号：R563.9[医药卫生—呼吸系统]